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ABSTRACT 
Although it is more than 100 years since Robert Koch discovered the tubercle 
bacillus, and more than 40 years since effective chemotherapy became 
available, the incidence of tuberculosis is increasing in much of the 
developing world and has recently re-emerged as a public health problem in 
industrialized countries. This problem is compounded by the increase in host 
susceptibility to tuberculosis caused by co-infection with HIV (Human 
Immunodeficiency Virus) and the emergence of Mycobacterium tuberculosis 
strains that are resistant to the front line drugs. These factors highlight the 
urgent need for development of new drug classes to counter the threat posed 
by tuberculosis. 
The purpose of the present study was to develop a mouse model for 
Mycobacterium tuberculosis with the aim of determining the antimycobacterial 
activity of medicinal plants used by traditional doctors to treat tuberculosis in 
South Africa. Furthermore, the toxic effects of these medicinal plants in 
uninfected mice were determined. 
A field trip to the Northern Cape, Western Cape, Eastern Cape and Free State 
provinces was undertaken and medicinal plants used by traditional doctors to 
treat tuberculosis or its symptoms were collected, identified and examined for 
their therapeutic effects against Mycobacterium tuberculosis, determined using 
the mouse model. In addition, the effects of medicinal plants on the 
production of cytokines and granuloma formation in infected mice were 
examined. 
IV 
Six-to-ten week old C57BL/ 6 mice were infected with 107 viable 
Mycobacterium tuberculosis H37Rv strain by an aerosol exposure model. 
Bacterial growth was monitored by sacrificing infected but untreated mice at 
day 1, week 2 and week 4. Treatment with medicinal plant extracts was 
started 2 weeks after infection and continued for 2 weeks. An INH-RIF 
combination was used as positive controls. 
The bacterial load in infected but untreated mice increased by 1 log unit each 
week for 2 to 3 weeks. Bacterial loads were not detected in INH-RIF treated 
mice after 2 weeks of treatment. Treatment of mice with high doses of plant 
extracts was toxic. None of the tested medicinal plant extracts showed any 
activity against Mycobacterium tuberculosis. The production of IL-12 at week 4 
was suppressed/ decreased when plant extract A was given at different 
concentrations. The bacterial loads in the lungs of the plant extract A treated 
mice was higher than that of the untreated mice (p < 0.005). Histological 
analysis of the lungs also revealed a high number of bacilli and increased size 
of the formed granuloma. 
In conclusion, the selected plant extracts obtained by water extraction 
exhibited no anti-tuberculosis activity in the laboratory mouse model for 
Mycobacterium tuberculosis infection. Furthermore, it was also shown that 
some plant extracts suppressed the production of IL-12, which plays an 
important role in the host's defense against Mycobacterium tuberculosis. 
However, further work is required to test if treatment for longer periods 
exhibits antituberculous activity. 
V 
1.1 INTRODUCTION 
Chapter 1 
LITERATURE REVIEW 
Tuberculosis is an infection, often of a lifelong duration, caused by Mycobacterium 
tuberculosis. It can result in disease in virtually every organ system in the body, 
most prominently the lungs, characterized histologically by granuloma 
formation (1). The mouse is one of several animal models that can be used in the 
study of experimental tuberculosis infection. The mouse is cost-effective to use 
and relatively easy to handle. Like the majority of healthy humans, the mouse is 
able to generate a strong immune response to Mycobacterium tuberculosis. The 
usefulness of the mouse model has grown in parallel with the explosion of 
knowledge in the field of immunology. Thus, those studying immunity or 
immunopathology associated with tuberculosis in the mouse model have 
profited greatly from the large number of immunological reagents now available. 
Of these reagents, the great majority are monoclonal antibodies, which made it 
possible to study the key protein and lipoglycan molecules of the bacillus, to 
measure cytokines secreted by activated macrophages and T-cells (2). 
Current strategies for control of tuberculosis center on treatment with multi-drug 
regimens based on the very effective combination of Rifampicin and Isoniazid. In 
endemic areas, the diagnosis and treatment of smear positive patients are 
emphasized in order to interrupt the spread of the disease within the 
community. Obstacles to the success of this strategy are the difficulty of early 
diagnosis and operational problems associated with delivery of a treatment that 
involves administration of multiple drugs over a period of at least six months (3). 
Factors that have already compounded these difficulties include increases in host 
susceptibility to tuberculosis caused by co-infection with human 
immunodeficiency virus (HIV) and the emergence of Mycobacterium tuberculosis 
strains that are resistant to the front- line drugs. Therapy for tuberculosis is 
arduous due to its long duration and multi-drug regimens (3). These phenomena 
are responsible for the increasing demand for the development of new 
compounds to treat tuberculosis. Pharmaceutical companies have not perceived 
the development of new compounds as a high priority for the last 30 years. A co-
coordinated effort to screen general medicinal plants for activity against 
Mycobacterium tuberculosis may well prove worthwhile. 
In this chapter, epidemiology of tuberculosis globally and in South Africa is 
discussed and recent advances in understanding the host immune response to 
tuberculosis together with the pathogenesis of tuberculosis are highlighted. Also 
discussed are strategies for prevention, control and treatment of tuberculosis 
based on the first-line anti-tuberculosis drugs. 
1.2 TUBERCULOSIS 
1.2.1 EPIDEMIOLOGY 
The World Health Organization has rightly declared tuberculosis to be a global 
emergency because globally the incidence of tuberculosis is rising rapidly (WHO 
Bulletin, 2001). It is estimated that more than a third of the world population is 
infected with Mycobacterium tuberculosis (Table 1.1). Only about 5% of those 
infected develop active disease during the first few years following exposure, but 
this represents 8 million new cases of the disease and almost 3 million deaths 
occurring annually, the most for any single infectious disease (1). 
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Table 1.1 The global toll of tuberculosis 
Region People infected (Millions) 
Africa 171 
Americas* 117 
Eastern Mediterranean 52 
South-East Asia 426 
Western Pacific§ 574 
Europe and other 
Industrialized countriesj 382 
Total 1722 
*Excluding USA and Canada 
§Excluding Japan, Australia and New Zealand 
i USA, Japan, Australia and New Zealand 
New cases Deaths 
1400 000 660 000 
560 000 220 000 
594 000 160 000 
2480 000 940 000 
2 560000 890 000 
410 000 40 000 
8 004 000 2 910000 
The two essential factors for the rapid spread of tuberculosis are crowded living 
conditions, which favor airborne transmission, and a population with little 
natural resistance. Disease due to tuberculosis in populations is influenced by 
three distinct risks: 
• The risk of an individual in the community being infected with tubercle 
bacilli in a given time period. 
• The risk of the disease following shortly after such infection. 
• The risk of the disease occurring long after the original infection owing to the 
reactivation of latent bacilli (4). 
South Africa is burdened by one of the worst tuberculosis epidemics in the 
world, with disease rates more than double those observed in other developing 
countries and up to 60 times higher than those currently seen in developed 
countries. The tuberculosis problem in South Africa is largely a result of 
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fragmented health services (5). In South Africa, a high proportion of the 
population lives under poor conditions and this may lead to the burden of the 
disease becoming uncontrollable. Estimates by the Medical Research Council's 
(MRC) National Tuberculosis Research Programme (TBRP) put the burden of 
tuberculosis for the year 2000 at 273 365 new cases, of whom 113 945 were to be 
infectious and 46,7 would also be HN positive (Table 1.2). In the year 2000 South 
Africa was also expected to contribute at least 15 % of the total tuberculosis 
caseload for Africa. The burden of tuberculosis is not distributed evenly 
throughout South Africa and rates vary considerably among the nine provinces 
(Fig 1.1). 
Fig 1. 1 Tuberculosis rates in the 9 provinces of South Africa 
South Africa 
· 244 
-; 
316 
Provinces.shp 
Northern Provine~ 
... Mpumalanga 
, 11111 North West 
Gauteng 
Natal 
-- Eastern Cape 
Free State 
Western Cape 
Northern Cape 
lllcidence rates per 100 000 POOUlatlon in 1997/98 {National health office, Pretoria) 
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Table 1.2 Annual tuberculosis burden for South Africa: 600 total cases per 100 
000 population; 250 smear-positive cases per 100 000 population. 
Province Total TB cases Proportion HIV+ 
Northern Province 23338 36.3% 
Mpumalanga 15 657 59.1% 
North West 15 549 45.5% 
Gauteng 45598 44.8% 
Free State 14654 51.7% 
Kwazulu-Natal 65 695 64.6% 
Eastern Cape 56495 40.0% 
Northern Cape 4649 33.2% 
Western Cape 34 211 31.6% 
South Africa 273 365 47.6% 
1.2.2 TRANSMISSION OF TUBERCULOSIS 
The principal risk of acquiring infection with Mycobacterium tuberculosis is 
breathing (1,4). Tuberculosis causing microbes are present in sufficient 
concentrations in the air to cause infections and disease. Central to the concept of 
airborne transmission is the droplet nucleus, a microscopic particle 1 - 5 microns 
in size, consisting of no more than 2 or 3 viable bacteria surrounded by a layer of 
moisture. Once in air, water evaporates from the surface of the particle, 
decreasing its size and concentrating its contents of microbes. 
These particles form droplet nuclei in which evaporation continues until the 
vapor pressure of the droplet equals the atmospheric pressure. The droplet 
nuclei are very stable, settle very slowly and remain suspended in the air for 
very long periods. Droplet nuclei are produced when a patient with active 
pulmonary or laryngeal tuberculosis coughs, speaks, sneezes or sings. Coughing 
can produce 3000 infectious droplet nuclei, talking for 5 minutes an equal 
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number and sneezing can produce over a million particles with a diameter of less 
than 100nm (Riles et al, 1961). 
Breathing on its own does not produce these particles. When breathed in, droplet 
nuclei are not deposited on the walls of the upper airways, trachea or bronchi, 
they remain suspended in the airway until they reach the alveoli. Larger particles 
that are deposited on the airway are removed through normal mechanism of 
airway clearance. Factors determining the likelihood of transmitting tuberculosis 
infection are: 
• Number of organisms 
When many infectious bacillary particles are inhaled, a phenotypically hardy 
bacillus is likely to be among them. Pulmonary infection would begin only after a 
strongly endowed bacillus is ingested by a weakly endowed alveolar 
macrophage. No one knows exactly how many particles containing tubercle 
bacilli must be inhaled before such a combination is reached; for human beings, 
the figure is probably between 5 and 200 (6). 
• Virulence of organisms 
Tubercle bacilli may, both genetically and phenotypically, vary in virulence. The 
virulence of human-type tubercle bacilli (H37Rv) can sometimes be reduced by 
repeated sub culturing, indicating that its genotype is not completely stable. A 
viable bacillus that is dried out or exposed to sunlight will often be 
phenotypically too weak to initiate an infection. A viable bacillus kept moist in a 
dark place will be more infectious when aerosolised (6). 
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1.2.3 PATHOGENESIS 
Airborne droplet nuclei containing very few or even single infectious units are 
small enough to avoid entrapment by the bronchial mucociliary apparatus and 
reach the terminal air space where multiplication begins. The heavier bacillary 
particles (containing more bacilli and/ or bits of caseous material) impinge upon 
the mucosa! surfaces of both the nasopharynx and the bronchial tree, are moved 
along the cilia, and are eventually swallowed or they are coughed up and 
destroyed (6). 
The initial focus is usually subpleural in location and usually located in the 
midlung zone where greater airflow favors deposition of inhaled bacilli. The 
inhaled bacillus reaches the alveoli and is ingested by an alveolar macrophage. In 
such macrophages the bacillus can be destroyed or inhibited or can multiply 
intracellularly. If the bacillus multiplies, the alveolar macrophage dies and it's 
bacillary load are ingested by other alveolar macrophages emigrating from the 
pool of circulating monocytes. However, bacterial multiplication tends to be 
mostly unimpeded, eventually destroying the macrophages. The tubercle bacilli 
multiply within tissue macrophages in a state of symbiosis, where most of the 
intracellular bacilli and most of the macrophages containing them live in 
apparent harmony. Logarithmic growth of the bacilli occurs from day 7 to day 21 
(7). 
In 3 - 4 weeks however the immune system responds. This is characterized by 
the onset of Cell Mediated Immunity and Delayed Type Hypersensitivity. 
Alveolar macrophages now lymphokine activated by T- lymphocytes, 
demonstrate an increased ability to destroy intracellular bacilli. As a result, the 
logarithmic increase in the number of organisms ceases. At the same time bacilli 
kill macrophages and their bacillary load is often ingested by nearby 
macrophages. These cells in turn will die if the bacilli multiply within them. A 
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tubercle forms that consists of a caseous necrotic center surrounded by 
granulation tissue containing viable macrophages, lymphocytes and other cell 
types. 
The caseous center will then grow, and the lesion will enlarge. Liquefaction of 
the caseous centers of tubercle is one of the most harmful host responses in 
tuberculosis. Liquefaction seems to be due to hydrolysis of the protein, lipid and 
nucleic acid components of caseous tissue by the hydrolytic enzymes in the 
macrophages. Liquefaction perpetuates tuberculosis in humans. The liquefied 
caseum is an excellent culture medium for the tubercle bacillus. In this 
environment, the bacillus extensively multiplies extracellularly for the first time 
and attains large numbers. This large antigenic load is toxic to tissues. The walls 
of the nearby bronchi often become necrotic and rupture, forming a cavity. 
Delayed Type Hypersensitivity continues to the point of cavity formation and 
destruction of cavity walls. The bacilli and bits of liquefied and caseous tissue 
are then discharged into the airway reaching other parts of the lung and the 
outside environment (6,7). 
1.2.4 IMMUNOLOGY OF TUBERCULOSIS 
Tuberculosis is the prototype of infections that require cellular immune response 
for their control. In the first few weeks the host has almost no specific immune 
defense against infection by Mycobacterium tuberculosis. Small inhalation inocula 
multiply freely in the alveolar space or within alveolar macrophages. 
Unrestrained bacterial multiplication proceeds until the development of tissue 
hypersensitivity and cellular immunity supervene. 
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Mycobacterium tuberculosis adheres to alveolar macrophages via multiple 
complement receptors (CRl, CR3, CR4, etc) and then internalized into a 
phagosome where it may be killed (8). The intracellular mechanisms for killing or 
inhibiting growth of Mycobacterium tuberculosis in alveolar macrophages include 
the production of nitric oxide (NO) and reactive oxygen intermediates (ROI) as 
well as apoptosis induced by H202 or cytotoxic T-cells. Alveolar macrophages 
can also participate in a broader context of cellular immunity through the process 
of antigen presentation and recruitment of T-lymphocytes. 
Macrophages present antigens processed in phagosomes via major 
histocompatibility complex (MHC) class 11 molecules to CD4 T-lymphocytes, the 
major effector cells in cell-mediated immunity. The antigens bind to T-cell 
receptors on the surface of the T-lymphocytes. These CD4 T-lymphocytes tend to 
polarize into Thl cells producing predominantly interferon gamma (IFN-y) and 
interleukin 2(IL-2) or Th2 cells producing predominantly IL-4, IL-5, IL-6, IL- 10 
and IL-13. In mice, immunity correlates with a Thl response. Macrophages 
infected with Mycobacterium tuberculosis secrete IL-12, which induces the 
secretion of IFN-y by CD4 cells and natural killer cells. The IFN-y enhances the 
activation of macrophages and improves their ability to contain the spread of 
Mycobacterium tuberculosis (2,7,8). However Mycobacterium tuberculosis is not 
defenseless. It can produce ammonia to counteract phagosomal acidification. Its 
lypoglycan coat (LAM) can actively scavenge toxic radicals produced against it 
by the macrophage as well as produce enzymes such as superoxide dismutase to 
inactivate radicals. 
9 
1.2.5 TREATMENT OF TUBERCULOSIS 
Before effective drugs were available, half of the patients with active pulmonary 
tuberculosis died within 2 years, and only a quarter were cured. With the advent 
of chemotherapy, protracted bed rest, lengthy isolation, and collapse therapy 
became unnecessary, and in theory at least, successful treatment was a 
reasonable goal in all adults (9,10). 
Current therapy for pulmonary tuberculosis involves 6 months of treatment with 
Isoniazid, Pyrazinamide, Rifampin and Ethambutol or Streptomycin for reliable 
treatment therapy. The long treatment therapy increases the probability of non-
compliance, leading to the generation of multidrug-resistant isolates of 
Mycobacterium tuberculosis. Current therapies reduce the pulmonary bacterial 
burden, but treatment periods of 6 months for nonimmunosuppressed 
individuals and at least 9 months for immunosuppressed patients are required 
for reliable treatment efficacy (4, 10). 
• ISONIAZID (INH) 
0 
~(NH2 
~~ H 
Fig 1.2. Structure oflsiniazid 
INH is the cornerstone of therapy and should be included in all regimens unless 
a high degree of INH resistance exists. INH acts almost exclusively against M. 
tuberculosis, M. bovis and M. africanum. INH is highly selective. This remarkable 
selectivity in its action is thought to be mediated by the bacterial enzyme catalase 
peroxidase which catalyses the reaction converting INH to a potent bactericidal 
derivative. INH is bactericidal at minimal inhibitory concentration (MIC) levels 
of less than 0.1 g/ml for 80% of susceptible strains of M. tuberculosis (10). 
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MECHANISM OF ACTION 
INH may be bacteriostatic or bactericidal in action, depending on the 
concentration of the drug attained at the site of infection and the susceptibility of 
the infecting organism. The exact mechanism of action of INH has not been fully 
elucidated, but several mechanisms including interference with metabolism of 
bacterial proteins, nucleic acids, carbohydrates, and lipids have been proposed. 
One of the principal action of the drug appears to be inhibition of mycolic acid 
synthesis in susceptible bacteria, which results in loss of acid-fastness and 
disruption of the bacterial cell wall. INH is bacteriostatic for "resting" bacilli but 
is bactericidal for rapidly dividing microorganisms. Susceptible bacteria may 
undergo 1 or 2 divisions before multiplication is arrested. 
TOXICITY 
The hepatotoxicity associated with INH result from the toxic effect of an 
intermediate product produced by N-hydroxylation of monoacetylhydrazine, 
one of the metabolite of INH, by the liver cytochrome P-450 mixed function 
oxidase system (Holdiness et al, 1984). Mice are most sensitive to INH and, 
surprisingly, the method of administration has scarcely any effect on toxicity in 
this species (10). 
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• RIFAMPICIN (RMP) 
lL 0 
0 ---',,-----I.:~ 
CHO 
3 
Fig 1.3. Structure ofRifampicin 
Rifampicin is the second major antituberculous agent. RMP is a semi synthetic 
derivative of one of a group of structurally similar, complex macrocyclic 
antibiotics produced by Streptomyces Mediterranei. RMP inhibits the growth of 
most gram-positive bacteria as well as many gram-negative microorganisms. 
RMP in concentrations of 0.005 - 0.2 g/ ml inhibits the growth of M. tuberculosis in 
vitro. RMP is soluble in organic solvents and in water at acidic pH. It is used in 
conjunction with other antituberculosis agents in the treatment of clinical 
tuberculosis. 
MECHANISM OF ACTION 
RMP inhibits DNA-dependent RNA polymerase of mycobacterium and other 
microorganisms by forming a stable drug-enzyme complex, leading to 
suppression of initiation of chain formation (but not chain elongation) in RNA 
synthesis. More specifically, the subunit of this complex enzyme is the site of 
action of the drug, although RMP binds only to the holoenzyme. Nuclear RNA 
polymerase from a variety of eukaryotic cells does not bind RMP, and RNA 
synthesis is correspondingly unaffected. While RMP can inhibit RNA synthesis 
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in mammalian mitochondria, considerably high concentrations of the drug are 
required than for the inhibition of the bacterial enzyme. RMP is bactericidal for 
both intracellular and extracellular microorganisms (10,11,12). 
TOXICITY 
In humans acute overdose with RMP doses up to 12g have not been fatal, at least 
one fatality has been reported following ingestion of a single 60g dose of the 
drug. The lethal dose (LD50) of RMP in mice is 0.885g/kg. The most important 
complication of RMP is Hepatitis. This occurs 4 times more frequently in 
regimens containing both INH and RMP than those containing INH alone. 
• PYRAZINAMIDE (PZA) 
0 (]rNH2 
N Fig 1.4. Structure of Pyrazinamide 
PZA a derivative of niacinamide, is a synthetic antituberculosis agent. PZA is 
active against tubercle bacilli, perhaps because it possesses an enzyme 
pyrazinamidase, which transforms PZA into pyrazinoic acid believed to be 
intracellularly active substance. Currently, PZA is considered a first line agent 
and is the third most important drug used in the treatment of tuberculosis. Its 
beneficial effect is mostly limited to the first 2-4 months of treatment. 
MECHANISM OF ACTION 
PZA may be bacteriostatic or bactericidal in action, depending on the 
concentration of the drug attained at the site of infection and the susceptibility of 
the infecting organism. In vitro and in vivo, the drug is active only at a slightly 
acidic pH. The exact mechanism of action of PZA has not been fully elucidated. 
The antimycobacterial activity of PZA appears to partly depend on conversion of 
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the drug to pyrazinoic acid (POA). Susceptible strains of M. tuberculosis produce 
pyrazinamidase, an enzyme that deaminates pyrazinamide to POA, and the in 
vitro susceptibility of a given strain of the organism appears to correspond to its 
pyrazinamidase activity. In addition, the fact that POA lowers the pH of the 
environment below that which is necessary for M. tuberculosis growth appears to 
contribute to the drug's antimycobacterial activity in vitro (11,12). 
TOXICITY 
The most frequent adverse effect of PZA is hepatotoxicity. Hepatotoxicity is a 
problem when PZA is given in larger doses and for longer periods. 
Hepatotoxicity may appear at any time during therapy. When it is used in short-
course therapy no increase in the incidence of hepatotoxicity is noted. In mice 
PZA has a LD50 of 3.4g/kg following oral administration (Robinson et al, 1954). 
Higher doses results in excitation, rapidly followed by depression. 
• ETHAMBUTOL (EMB) 
H 
I H OH 
H3C/"yN-------..N~CH3 
H'\._oH I 
H Fig 1.5. Structure ofEthambutol 
EMB is a synthetic antituberculosis agent. EMB is a highly specific agent and is 
active only against organisms of the genus Mycobacterium. It is active in vitro and 
in vivo against M. tuberculosis, M. bovis, M. marinum and some strains of M. 
kansasii, M. avium and M. intracellulare. EMB is usually given at a daily dose of 
25mg/kg during the first 2 months of well-supervised therapy and at 15mg/kg 
for longer often less well-supervised periods. 
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MECHANISM OF ACTION 
EMB is bacteriostatic in action. Although the exact mechanism of action has not 
been fully elucidated, the drug appears to inhibit the synthesis of one or more 
metabolites in susceptible bacteria resulting in impairment of cellular 
metabolism, arrest of multiplication, and cell death. EMB is active against 
susceptible bacteria only when they are undergoing cell division (12). 
TOXICITY 
A single administration of EMB has only a low toxicity in mice (Diermeier et al, 
1966). In humans adverse effects of EMB include dermatitis, pruritus, headache, 
dizziness, fever and mental confusion among other things. 
1.2.6 PREVENTION OF TUBERCULOSIS 
The outcome of mycobacterial infection critically depends on the host immune 
response. In most individuals, infection with Mycobacterium tuberculosis induces 
an immune response sufficient for protection against progression to primary 
disease. BCG vaccine reproduces as near as possible the initial natural infection 
but does not impose a disease risk. BCG vaccine, which is derived from a strain 
of M. bovis attenuated through years of serial passage in culture, was first used 
in 1921 to protect against tuberculosis in human (3). Many BCG vaccines are 
available worldwide; all are derived from the original strain but vary in culture 
characteristics and in ability to induce sensitization to tuberculin. BCG vaccines 
vary because of genetic changes in the bacterial strain and because of differences 
in techniques of production, in methods and routes of vaccine administration. 
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BCG vaccine is currently administered to 100 million young children each year 
throughout much of the world. This is to protect children against primary and 
disseminated forms of tuberculosis. That is why it should be administered only 
to tuberculin-negative persons. While BCG vaccine does not prevent infection, it 
usually prevents progression to clinical disease, and its effectiveness in 
preventing disseminated disease in children is striking (3). BCG should not be 
given to persons with established HIV infection. 
1.2.7 CONTROL OF TUBERCULOSIS 
The WHO-recommended treatment strategy for detection and cure of 
tuberculosis is Directly Observed Treatment System (DOTS). DOTS combines 
five elements: political commitment, microscopy services, drug supplies, 
surveillance and monitoring systems and use of highly efficacious regimes with 
direct observation of treatment. Once patients with infectious tuberculosis have 
been identified using microscopy services, health and community workers and 
trained volunteers observe and record patients swallowing the full course of the 
correct dosage of anti-tuberculosis medicines. Sputum smear testing is done 
after 2 months, to check progress, and again at the end of treatment. A 
recording and reporting system documents patients' progress throughout, and 
the final outcome of treatment. 
General strategies for controlling TB 
• Early identification and treatment of persons with infectious 
tuberculosis. This does not only cure the affected person but also renders 
the patient non-contagious within a few weeks. 
• Identifying and treating persons with non-contagious tuberculosis. This 
is useful in preventing progression of infection to clinical disease. 
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• Use of ventilation and ultraviolet lights to decontaminate air containing 
infectious droplet nuclei. This is used routinely only where the risk of 
transmission is known to be exceptionally high. 
• Vaccination of uninfected children who are at unavoidable risk of 
exposure to tuberculosis and for whom other methods of prevention and 
control have failed or are not feasible. 
In South Africa some progress is being made in certain provinces. Mpumalanga 
and the Western Cape are already showing dramatic improvements in cure 
rates, because of disciplined implementation of the DOTS strategy of the WHO. 
Other provinces are at various stages of implementation of the process (5). 
1.3 CONCLUSION 
Increased knowledge of current risks of infection and subsequent disease could 
help greatly in efforts to bring tuberculosis back under control and, in 
developed countries, could even lead to its elimination in the near future. 
Progress towards understanding of immune response to mycobacterium has 
accelerated in the last decade, but it remains for this progress to be translated 
into practical advances relevant to the control of tuberculosis. New 
understanding of the immunology of tuberculosis offers a promise of new and 
advance modalities. It is reasonable to expect the pace of progress to continue 
to increase, driven by the magnitude of the global problem compounded by the 
pandemic of HIV infection and outbreaks of multidrug-resistant tuberculosis. 
The human immune response to Mycobacterium tuberculosis is a complex 
reaction that is both beneficial and deleterious to the infected individual. It 
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requires the interaction of several types of cells that cross-regulate each other's 
activities via mixture of soluble cytokines. The latter often must act in concert 
or sequentially to stimulate a given cellular function and may have opposing 
effects on different cell types. Advances in basic biology now render it possible 
to directly analyse immune response in infected or diseased human tissues and 
body fluids. This approach should permit a reappraisal of concepts based on 
older models and improve our understanding of the pathogenesis of human 
tuberculosis infection and disease. 
Adherence to medical treatment depends on the characteristics of the 
treatment, the characteristics of the health-care delivery system, and the 
patient/health-care worker bond. Having bilingual and bicultural staff if the 
patient population speaks languages other than the dominant one enhances the 
relationship between the patient and all members of the tuberculosis-control 
program team. 
A better understanding of the biology of Mycobacterium tuberculosis will 
hopefully address such issues as developing medications or modulators that 
can kill the organism in the actively and intermittently metabolizing, as well as 
dormant phases, developing medications that will both shorten treatment and 
allow it to be given intermittently, as was the case with Rifampin, activating 
dormant organisms so that drugs can work against them, and determining how 
to better prevent drug resistance. 
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CHAPTER2 
TRADITIONAL MEDICINE 
2.1 INTRODUCTION 
The use of plants or plant extracts for medicinal purposes has been going on for 
thousands of years, and herbalism and folk medicine, both ancient and modern, 
have been the source of much useful therapy (13). 
Traditional medicine has been practiced for at least seven thousand years. To this 
day, the majority of the world's populations receive their health care from 
traditional medicinal systems. The practices are based on beliefs that were in 
existence before the development and spread of modern scientific medicine, and 
that are still prevalent today. Traditional medicine is part of a country's cultural 
heritage handed down from generation to generation. Experimentation with 
plants and the passage of knowledge from one generation to the next resulted in 
the development of a vast knowledge about plants for use as foods, medicines 
and their method of preparation (13,14). Millions of people worldwide still 
depend upon traditional therapies that are based on medicinal plants, often 
administered in very specific ways under the direction of a knowledgeable 
healer. Plants have long been used among indigenous South Africans as 
remedies against infectious diseases. It is estimated that 70 - 80% of the 
indigenous people of South Africa still consult traditional healers for curing their 
diseases (14). Many plant preparations have been used externally as disinfectants 
and antiseptics for wounds and pimples, as antidiarrhoeics and in the treatment 
of respiratory diseases (15). 
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Tuberculosis is a leading contender for the dubious distinction of being the most 
important plague to humankind. Tuberculosis has also been termed as the 
"disease of the poor". This is because a large proportion of tuberculosis 
incidences come from countries of poor economic status and associated 
malnutrition. A large proportion of them rely on traditional means of health. 
Among the many forms of treatment they use are herbal preparations. Many of 
these herbal medicines have been used from generation to generation with great 
confidence of efficacy (8) 
In this chapter, collection of plants from the field trip is discussed. Furthermore, 
perceptions and understanding of tuberculosis by traditional doctors is 
discussed. Methods of diagnosis and treatment procedures by traditional doctors 
are also mentioned. 
2.2METH0DS 
2.2.1 PLANT COLLECTION 
We consulted traditional healers, herbalists and Sangomas (Traditional doctors) 
on the plants they use to treat tuberculosis or chest problems. The plants were 
then either bought from them or collected in the field with their help. 
Information on the part of the plant used, how it is prepared, how it is 
administered and how much is taken was noted. Traditional names of plants 
were given in almost all cases and their botanical names were 
checked/ confirmed on the traditional medicine database at the Department of 
Pharmacology, UCT. 
2.2.2 PLANT PREPARATION 
The collected plant material was air-dried at room temperature. The dried 
material was ground using the laboratory blender (Waring products, U.S.A) to 
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increase the surface area of the plant for extraction. The ground plant material 
was mixed the same way traditional doctors prepare their remedies. 
Table 2.1 Plants used for tuberculosis 
Symbol Vernacular name Botanical name Part used 
A Wynruit Ruta graveolens Leaves 
Sieketroos Arctopus echinatus Root 
Varkoor Cotyledon orbiculata Leaves 
B Iphuzi Gunnera perpensa Root 
Umagaqana Croton sylvaticus Tuber 
C Undawuluthi Sparaxis grandiflora Tuber 
Isibhara Warburgia ugandensis Root 
Ubuvimba Withania somnifera Root 
D Rooiwortel Bulbine natalensis Root 
Bergsalie Buddleia salvifolia Leaves 
Koorsbos Dicoma capensis Leaves 
E Iqwili Alepidea prunelloides Root 
African potato Hypoxis hemerocallidea Tuber 
F Varkoortjies Centella asiatica Leaves 
G Inqwebeba Ledebouria revoluta Root 
Mathonga Eucomis autumnalis Bulb 
H Isicimamlilo Pentanisia prunelloides Root 
I Isibhara Warburgia ugandensis Root 
J Umdlavuza Eucalyptus qlobulus Bark 
Umkhwenkhwe Pittosporum viridiflorum Bark 
K Iphuzi Gunnera perpensa Root 
Iqwili Alepidea prunelloides Root 
21 
2.2.3 EXTRACTION 
Known amount of the plant material was extracted using water as a solvent. Hot 
and cold extraction of the plant material was carried out for 24 hours each, 
followed by filtration of the extracts using a Whatman filter paper (0.15cm, 
Millipore, Bedford, MA). Cold extraction was carried out on the shaker (Labcon, 
labdesign engineering, Maraisburg) and hot extraction on the Soxhlet apparatus 
(Appendix A). The filtrates were concentrated by freeze-drying the water 
component on the freeze-drier and the yields calculated. The extracts were stored 
in the freezer at 4°C until use. 
2.2.4 FIELD TRIP 
Before starting the project a field trip was undertaken to the Northern Cape, Free 
State, Eastern Cape and the Western Cape provinces (Fig 2.1). In the Northern 
Cape we were interested in knowing how the Khoisan people treat tuberculosis 
in their communities. This is because little information is known about their 
traditional healing systems. Khoisan people use small trees to treat diseases 
because they live in a semi desert place where there are no big trees. In other 
regions, barks and leaves from big trees are used in the treatment of tuberculosis. 
We also found that in different regions different plants were prescribed for the 
treatment of tuberculosis. It was not possible, however, to record the response of 
the medicinal plant therapy as patients were not readily available for interview 
at the time of the visits. Moreover, traditional doctors have no organized 
hospitals and the sick that receive treatment are always outpatients. 
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SOUTH AFRICA 
Port Nolloth 
Fig 2.1 The route of the field trip. The trip took 2 weeks and the plant material was 
either bought or collected in the field with the help of the traditional doctor. 
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2.2.5 PERCEPTION AND UNDERSTANDING OF TUBERCULOSIS BY 
TRADITIONAL DOCTORS 
According to Traditional beliefs tuberculosis is a man made disease. A 'big 
cough' according to most healers is caused by sorcery. This is practised in order 
to inflict harm upon some specific enemy, for instance as a response to a 
grievance in a relationship. The person causing the disease does this by burying 
bad medicine in the ground and when the victim steps on it will penetrate the 
foot and cause a disease such as tuberculosis or by giving the victim 'poisoned' 
food to eat which will cause a disease such as tuberculosis in the body. 
Once the bad medicine or 'poisoned' food is in the body, it will go to the lungs 
where it will cause an internal growth because of 'germs' from it. The germs lead 
to coughing and weight loss. Like western doctors, traditional doctors also 
believe that this kind of disease is transmissible and the person suffering from 
this should always use a handkerchief when blowing his/her nose or hold it in 
front of his/her mouth when coughing. 
2.2.6 DIAGNOSIS AND TREATMENT OF TUBERCULOSIS BY 
TRADITIONAL DOCTORS 
When a patient visits a traditional doctor for consultation on a specific disease, 
the traditional doctor will throw bones to communicate with the ancestors in 
order for them to show him/her the cause and the solution to a specific disease. 
During this process, the traditional doctor will advise the patient as to the 
presenting problem and the reasons or dynamics underlying the malady. The 
ancestral spirits will then tell them which plant they have to use to treat a 
particular problem of a patient and where they can find the plant. This is then 
followed by advice referring to a treatment approach. In most cases, this includes 
prescribing a herbal remedy. 
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Treatment is most often directed both to the body and to the mental state, 
considered in the context of social environment, ancestral spirit, family and 
community. The treatment chosen is not only symptomatic, it relates to the 
evolution of the disorder. This in many cases involves giving different herbal 
preparations for the symptoms as well as the cause of the health problem. One 
remedy can also contain different plants with different effects. Some traditional 
doctor's reported that they send some patients to nearby hospitals to confirm or 
to help them in their diagnosis. 
2.2.7 CURRENT RESEARCH IN TUBERCULOSIS AND MEDICINAL 
PLANTS 
With the urgent need for new antimycobacterials, South African researchers are 
now beginning to find safer, rapid and effective ways of assaying plants against 
Mycobacterium tuberculosis. Although no marketable products for the treatment of 
tuberculosis have been isolated from plants, some lead molecules have been 
isolated (16). In structure-activity related studies against Mycobacterium 
tuberculosis, many schools of thought have been suggested. Different research 
groups have found activity on a variety of natural products with no certain trend 
towards a specific group of compounds. Focus is also paid to the marine-derived 
natural products, although these are not necessarily of the phytoplankton family 
(17). 
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2.3RESULTS 
Table 2.2 Yields of plant extractions 
Extract Starting mass (g) Final mass (g) Percentage yield (%) 
A 13.67 1.59 11.63 
B 5 1.70 34.00 
C 6 1.42 23.66 
D 15 2.27 15.13 
E 10 2.24 22.40 
F 20 3.76 18.80 
G 50 5.24 10.48 
H 10 1.23 12.30 
I 10 2.65 26.5 
J 10 2.74 27.40 
K 5 0.90 18.00 
2.4 DISCUSSION 
South Africa is a country where majority of people still live below the breadline 
level. The first person to be exposed to these poor people when they get sick is 
the local traditional doctor. This is because of the traditional doctor's convenient 
hours and the more personalised service, their offer of a wide variety of curative 
services and because they are more accessible to the general population. 
Although not part of the modern health care system in our country, traditional 
doctors perform a significant role in our society, especially in the rural areas. 
There should be strengthening of links between modern and traditional medicine 
practices with the emphasis on improving mutual understanding especially 
about the practices and techniques of the traditional practitioners. 
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CHAPTER3 
DETERMINATION OF THE THERAPEUTIC AND TOXIC EFFECTS OF 
MEDICINAL PLANTS 
3.1 INTRODUCTION 
South Africa is witnessing an explosion in the number of tuberculosis cases 
because of the AIDS pandemic. It is essential to have new antituberculosis 
agents, preferably those that can be readily and simply produced from some 
local source. The use of antimicrobials from natural vegetation has a great impact 
on human health care in undeveloped countries (18). Traditional doctors use a 
mixture of medicinal plants to treat tuberculosis or its symptoms. In South Africa 
some patients, especially from rural areas might use these medicines for 
treatment of tuberculosis. Although these medicines are used extensively to treat 
tuberculosis or its symptoms, there is little or no information on their toxic 
effects. Thus, it is important to determine the toxic and therapeutic effects of 
these medicines. The importance in identification of herbal molecules lies not 
only in their pharmacological or chemotherapeutic effects but also in their role as 
template molecules for the discovery of new drug substances. 
In this study, plants used to treat tuberculosis or its symptoms by traditional 
doctors were investigated for their therapeutic effects against M. tuberculosis in a 
mouse model. Rifampin and Isoniazid are both first-line drugs for use in the 
therapy of tuberculosis and are included in the list of recommended drug 
regimens for treatment of latent M.tuberculosis infection in adults. As a part of 
this study, we decided to use them as positive controls. 
27 
3.2 MATERIALS AND METHODS 
3.2.1 Mice 
In all experiments, six to eight weeks old C57BL/ 6 wild type mice were used. 
Mice were bred and maintained under specific pathogen free (SPF) conditions in 
the animal unit at the University of Cape Town (UCT), South Africa. The animals 
were housed in filter-top cages (5 per cage) and were given food and water ad 
libitum throughout the study. Mice were allowed to acclimatize to their new 
environment for 3 - 5 days prior to infection. 
3.2.2 PREPARATION OF INFECTIOUS MYCOBACTERIUM TUBERCULOSIS 
3.2.2.1 Cultivation 
Mycobacterium tuberculosis H37Rv was obtained from Department of 
Immunology, UCT, Cape Town. A small amount of colony was removed from a 
Lowenstein-Jensen slant using a sterile plastic disposable inoculating loop, and 
deposited into a 50ml, 25cm2 sterile screw-capped tissue culture flask (Greiner 
Labortechnik) containing 10ml of Middlebrook 7H9 Broth [Difeo]/ 10% OADC 
(oleic acid-albumin-dextrose-catalase) enrichment media (State Vaccine Institute, 
Cape Town). Culture flasks were incubated at 37°C in a CO2 incubator and 
shaken daily to gently agitate the broth. Incubation proceeded for 1-2 weeks until 
the culture turned turbid (CFU density of 1 X 107 / ml) and in the mid-late log 
growth phase. From this culture 20ml was carefully transferred into a 250ml 
sterile screw-capped culture flask (Greiner Labotechnik) containing 90ml 
Middlebrook 7H9 Broth [Difeo]/ 10% OADC enrichment medium. Culture flasks 
containing 100ml of broth were further incubated for 1-2 weeks at 370c in a CO2 
incubator and shaken daily until a similar turbidity was attained. Aliquots of 
these mid-late log phase cultures were aseptically prepared by pipetting 1ml per 
vial into sterile 2ml serum vials (Greiner Labotechnik). These aliquots were 
placed into a labelled storage box within a -70°C freezer until further use. An 
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placed into a labelled storage box within a -700C freezer until further use. An 
aliquot (2ml) of the bacilli culture was plated on the blood agar and incubated 
overnight to screen for any contamination. 
3.2.2.2 Inoculum determination- Colony Forming Units (CFU) 
The concentration of the bacilli was determined by making 10-fold serial 
dilutions in 0.9% NaCl/0.04% Tween 80, and plating out dilutions of 10-2 to 10-7 
on Middlebrook 7H10 Agar (19g 7H10 Agar/lL [Difeo], 5ml glycerol, 10% 
OADC) on 2 compartment plates (90mm plates, Sterilin). These were incubated 
at 370c for 15-18 days and colonies counted using an inverted microscope (Wild 
MS Heerbrugg). 
3.2.3 AEROSOL INFECTION OF MICE 
3.2.3.1 Preparation of Inoculum for Aerosol Infection 
An aliquot of Mycobacterium tuberculosis was thawed at room temperature, spun 
down at 4 000 rpm (revolutions per minute) for 5 minutes, the supernatant 
discarded and the pellet resuspended 30 times using a 1ml syringe fitted with 
26.5 gauge needle (Sterilin) in a total volume of 6ml 0.9% saline to disrupt 
clumping. To obtain the desired rate of infection, the inoculum was prepared 5 
log10 CFU higher than what one requires delivered into the lungs of the infected 
mice (the aerosol machine is programmed to deliver into the lungs 
approximately 5 log10 CFU lower than the inoculum nebulised) i.e. To obtain 100 
CFU /lung, the mycobacterial suspension was prepared at 2.0 X 106 CFU / ml in a 
total volume of 6ml sterile 0.9% saline (1.0 X 107 CFU/5ml nebulised). To confirm 
the CFU / ml titer 10-fold serial dilutions of the inoculum from 10-1 to 10-7 were 
plated in duplicates on the Middlebrook 7H10 agar [Difeo]. 
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3.2.3.2 Aerosol procedure 
The aerosol exposure chamber (Middlebrook) was sterilized prior to use with a 
3% virkon solution followed by 70% ethanol. The metal support plate and the 
mesh exposure basket were placed into the chamber drum. The divisions within 
the drum were labelled with the sex of the mouse and the mice transferred from 
their cages into the basket. The basket lid was secured and the perspex chamber 
lid sealed by firmly snapping the latches. After sealing the chamber, the glass 
Nebuliser-Venturi was mounted to the compressed air and main airflow fittings, 
which was secured by 3 clamps. A safety mask was placed over the face for the 
rest of the procedure. Carefully, screw cap on the nebuliser was removed and 
5ml of the inoculum added into the bottom of the venturi using a 5ml syringe 
fitted with an 18-gauge needle (Sterilin). After screwing the lid closed, the 
instrument was switched on. 
The program to be entered for aerosolizing mice was as follows 
1. Preheating time = 15 minutes 
2. Nebulising time =40 minutes 
3. Oouddecay =40 minutes 
4. Decontamination= 15 minutes 
The preheating time is to enable the incinerator to achieve its core temperature of 
7900C in order to decontaminate the exhaust air. During the nebulisation cycle 
the compressed air is activated and passes though the venturi to the nebuliser to 
create droplet nuclei containing bacilli. These droplet nuclei are carried into the 
chamber containing the animals. The third cycle is "cloud decay" in which the 
aerosol chamber is purged with fresh air and the bacterial mist dissipated. 
During the final cycle the UV lamps are switched on to decontaminate the top 
surfaces of the basket. Once the instrument had initiated the preheat cycle, the 
main air flowmeter should indicate 60 cubic feet/hour (CFH), and should be 
adjusted with the control valve if necessary. 
30 
When the nebulising cycle is started, the compressed air flow meter should be at 
10 CFH, and adjusted if required. The room containing the chamber was then 
vacated until the process ended (110 minutes), and the door appropriately 
marked to prevent intrusion. After completion of the cycle, the instrument was 
switched off, the lid opened, and the mice returned to their cages. All the 
contaminated components were wrapped up, sterilized by autoclaving, scrubbed 
clean and then autoclaved once more. 
3.2.4 Determination of Initial Pulmonary Infection (Day 1) 
To determine uptake of Mycobacterium tuberculosis into the lungs of the mice, 5 
animals were sacrificed by cervical dislocation one day after aerogenic challenge. 
Entire lungs were removed and immediately placed into sterile tubes containing 
2ml sterile saline solution. After completion of all necropsies, individual lungs 
were transferred into a sterile 10ml perspex mortar and homogenized with a 
pestle secured in a drill (Black and Decker KD574CRE, 680W). Lung 
homogenates were plated in duplicate volumes of 100µ1 and 200µ1 on 
Middlebrook 7H10 agar in duplicates, incubated at 37°C for 15-18 days, and 
CFU' s enumerated. 
3.25 TREATMENT OF INFECTED MICE 
Treatment was started 14 days postinfection and mice divided into 5 per group. 
A control group of infected mice was sacrificed at the start of treatment (Early 
control group). A second group of infected but untreated mice was sacrificed 
two weeks after therapy was initiated (Late control group). Treatment was given 
once daily for 5 days by oral gavage except positive control (given in drinking 
water) for 2 weeks. Mice were injected with 0.2ml of the treatment solution using 
a 1ml syringe fitted with an atraumatic stainless steel oral dosing needle 
(Sterilin). 
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SUNDAY MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY SATURDAY 
Weigh Aerosol l(Sacrifice) 2 3 4 5 
mICe infection 
6 Weigh 7 8 9 10 11 12 
mICe 
13 Weigh 14(Start) 15 16 17 18(Stop) 19 
mice Sacrifice 
20 Weigh 21(Start) 22 23 24 25(Stop) 26(Sacrifice) 
mice 
Table 3.1. Experimental plan for treatment of tuberculosis. 
No treatment Thera1 given 
ro j Dr4 Day2I 
:: 2 weeks ::::: 2 WPPks 
i 
Aerosol infection with H37Rv i Start treatment euthanaJ 
Fig 3.1. Schematic diagram of the experimental design for therapy of tuberculosis in mice. 
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3.2.6 POSITIVE CONTROL 
A lg of Rifampicin (Sigma Chemicals Co, South Africa) was dissolved in 10ml 
DMSO (Dimethyl Sulfoxide) solution and a lg of Isoniazid (Sigma Chemicals 
Co, South Africa) was dissolved in 10ml of distilled water to make a O.lg/ml 
stock of each. From each stock 200µ1 was removed and added to a bottle 
containing 200ml of drinking water to make the final concentration O.lg/L. The 
bottle was changed weekly with fresh drugs. 
3.27 TEST COMPOUND 
For preparation of the test compound, crude plant extracts were weighed, 
dissolved in distilled water, and filter sterilized. Each animal received vehicle 
equivalent per kilogram of body weight (e.g. lOOmg/kg). The plant extracts 
were freshly prepared each morning prior to administration. 
3.2.8 CFU DETERMINATION IN ORGANS 
A day after the last dose of treatment, treated and control mice were 
anaesthetized with diethyl ether before cervical dislocation. The lung, liver and 
spleen were aseptically removed (a piece cut for histology), weighed and 
immediately placed into sterile tubes containing 2ml of 0.9% Tween/Saline. 
After all necropsies were completed, individual organs were transferred into 
sterile 10ml perspex mortar and homogenized with a pestle secured in a drill 
(Black and Decker KD574CRE, 680W). Ten-fold serial dilutions of the 
homogenates was plated in duplicates on Middlebrook 7Hl0 agar plates, 
supplemented with 10%0ADC and the plates incubated at 37°C in CO2 for 3 
weeks before counting the CFU' s. 
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3.2.9 TOXICITY DETERMINATION 
Uninfected mice were treated with the same crude plant extracts used to treat 
the infected mice. Treatment was orally by gavages for a period of 2 weeks. Mice 
were observed for weight loss, ruffled fur, hunched posture, survival rate and 
other signs of distress. A record was kept of all mortalities and signs of toxicity. 
Lungs of mice that died were removed and tissue samples prepared for 
microscopical examination in an attempt to identify the cause of death. After 
treatment was stopped surviving mice were further observed for 5 days. 
3.210 STATISTICAL ANALYSIS 
All tests for significance were performed using the Student t test, by the Sigma 
plot program. P values of < 0.05 were considered significant. Means ± standard 
errors of the means were determined. 
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3.3 RESULTS 
1. Establishment of aerosol infection model 
An animal model was established to evaluate the activity of traditional herbs 
used in the treatment of tuberculosis in South Africa. Laboratory infection with 
M. tuberculosis was established by exposing mice to mycobacterium, aerosolised 
at 1 X 107 cfu/ml. Day 1 sacrifice confirmed a delivery of between 100 - 130 
cfu/lung in the infected mice (Fig 3.3A). The bacterial count in the lungs of 
infected mice increased by 2 log units between day 1 and day 14 (p<0.05). There 
was no significant difference in bacterial count (p>0.05) between early-untreated 
control (Day 14) and late-untreated controls (Day 26). 
2. Inhibition of tuberculosis infection by INH-RIF combination 
Treatment of infected mice was initiated on day 14 after infection. Treatment 
was once daily for 5 days per week and lasted for 2 weeks, then mice were 
sacrificed. INH-RIF combination, which is used widely in the early stages of the 
infection with M. tuberculosis was used as a positive control in the animal model 
for the evaluation of the activity of medicinal plant extracts against M. 
tuberculosis. Treatment of mice with INH-RIF resulted in the reduction of 
bacterial loads to below detection levels (Fig 3.3B). 
3. Effect of herbal medicines 
To be able to determine the optimum range of doses at which the potency of the 
anti-bacterial activity and toxicity of the medicinal plant extracts, could be 
evaluated. Mice were treated with plant extracts at different doses. It was found 
that some extracts could not dissolve at 1000mg/kg and this dose proved to be 
toxic in some cases. Subsequently 100mg/kg of body weight was chosen in the 
investigation of the anti-tuberculosis activity of plant extracts. 
Treatment of mice with plant extract A, at different doses, did not inhibit the 
multiplication of the bacilli (Fig 3.4). Mice treated with plant extract A at 10, 100 
and 500mg/kg of body weight respectively, produced between 1.5 - 2 log units 
increase in viable bacterial count in the lungs as compared (p< 0.05) to late-
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untreated controls (LC). The increase in bacterial count suggested absence of 
antituberculous activity in plant extract A. 
The anti-tuberculosis activity of plant extracts could in part involve inhibition of 
the dissemination of the bacilli in the body. Therefore, the spread of the bacilli 
from the lungs to other body organs after treatment with plant extracts was 
investigated. Plant extracts did not inhibit the spread of the bacilli to other body 
organs. Mice treated with 100mg/kg of other plant extracts were not efficacious 
in causing the bacterial elimination from the sites of infection (Fig 3.5). There 
was no significant reduction in bacterial counts in the liver and spleen of treated 
mice and the late-untreated controls. 
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M. tuberculosis growth in C57BU6 infected mice Effects of INH-RIF on M. tuberculosis infected mice 
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Fig 3.3 Number of viable M. tuberculosis organisms in lung of infected C57BU6 mice (n=5). 
Lungs were aseptically removed, homogenized and plated out on agar plates for CFU counts. 
(A) Negative control - infected untreated mice sacrificed at different time points. (B) Mice 
treated with INH-RIF combination for 2 weeks. Results are means (solid bars) ± standard 
deviations (error bars). 
Effects of plant extract A on cfu counts of M. tuberculosis 
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Fig 3.4 Number of viable M. tuberculosis organisms in lungs, livers and spleens of infected 
mice (n=5) after once-daily treatment for 2 weeks with the same plant extract at different 
doses. Organs were aseptically removed, homogenized and plated out on agar plates for CFU 
counts. Bacterial uptake confirmation mice were sacrificed at day 1. infected untreated mice 
from control groups were sacrificed at 2 weeks [ early control (EC)] and at 4 weeks [late 
control (LC)] after infection. Results are means (solid bars)± standard deviations (error bars) 
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Fig 3.5. Number of viable M. tuberculosis organisms in lungs, livers and spleens of 
infected mice (n = 5) after once-daily treatment for 5 days per week for 2 weeks with 
different plant extracts at 1 OOmg/kg of body weight. Organs were aseptically removed, 
homogenized and plated on the agar plates for CFU's. Infected untreated mice from 
control groups were sacrificed at 4 weeks (late control [LC]) after infection. Results are 
means (solid bars)± standard deviations (error bars). 
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4. TOXIC EFFECTS OF PLANT EXTRACTS 
To be able to determine the optimum range of doses at which the potency of 
anti-tuberculosis activity of the plant extracts could be investigated, a toxicity 
study on non-infected mice was simultaneously carried out and subsequently, a 
lOOmg/kg of body weight was chosen for the investigation of anti-tuberculosis 
activity of plant extracts. Uninfected mice were given treatment for a period of 2 
weeks by oral gavages. For each plant extract, 5 mice per group were observed 
for mortality, weight loss, ruffled hair and hunched posture. 
As expected, before treatment was initiated the survival rate of the uninfected 
mice was 100%. Signs of reaction to treatment, observed shortly after dosing 
with crude plant extract Bat lOOOmg/kg, consisted of lethargy and pilo-erection. 
Mice in that group died 4 - 5 hours after the administration of the plant extract. 
They had hunched postures and ruffled hair on their death. Histology of the 
lungs revealed presence of blood in the alveolar spaces. Mice treated with the 
same extract at lOOmg/kg resulted in 80% survival rate (Fig 3.6). 
In most groups, survival rate was very high. In all groups where mice died, they 
started dying after treatment was initiated. Initiation of therapy resulted in 
minor loss of body weight during the first week and this normalized during the 
second week of treatment. No toxicity was observed in other groups during the 
course of therapy and plant extract administration was not associated with 
mortality. Survivors, as judged by external appearance and behavior, were 
apparently normal after 5 days of observation. This observation was 
substantiated by body weight gains (Table 3.2). 
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Fig 3.6. Effects of crude plant extracts on survival rates of uninfected C57BU6 mice (n = 5). Mice were 
given treatment by oral gavages for 2 weeks. (A) Mice treated with plant extract A at different doses. (B) 
Mice treated with different plant extracts at same dose of lOOmg/kg of body weight. PC- positive control 
given at O. lg/Lin drinking water. 
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Table 3.2 Group mean weight of mice dosed orally with different crude plant 
extracts 
Dose (mg/kg) Body weight (g) at 
Before treatment Weekl Week2 5 days after treatment 
A-10 20.46 19.62 21.60 22.36 
A-100 20.62 20.26 22.31 22.35 
A-500 25.52 23.28 24.45 25.52 
B-100 26.27 22.87 25.67 26.27 
C-100 17.34 16.90 17.59 19.33 
D-100 20.77 19.06 20.88 20.91 
E-100 19.44 18.35 19.46 19.02 
F-100 26.02 24.79 24.63 26.02 
G-100 26.38 25.26 25.42 26.38 
H-100 25.68 24.93 24.75 25.68 
I-100 24.32 23.77 24.80 24.32 
J-100 26.71 25.29 25.91 26.71 
K-100 23.53 23.44 24.80 26.78 
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3.4 DISCUSSION 
Multidrug therapy is the cornerstone of any effective treatment regimen, and it 
prevents the emergence of drug resistance. Today, INH-RIF combination for the 
treatment of tuberculosis is still used to treat and prevent tuberculosis 
worldwide. Quenel et al (96) were able to completely eliminate CFU from the 
lungs of M.tuberculosis infected mice using a combination of microspheres 
loaded with Rifampin and oral Isoniazid after 26 days of treatment. In another 
study, Lenaerts et al (20), managed to achieve clearance in the lungs and spleen 
of infected mice after 12 weeks of oral INH-RIF treatment. In this study, we were 
able to completely eliminate CFU from the lung, liver and spleen using INH-RIF 
combination in drinking water after 2 weeks of treatment. 
The most common usage of medicinal plants is as decoction or tea prepared by 
maceration with boiling water. This may in part be simply due to ease of 
preparation but also may reflect the involvement of water-soluble substances, 
however some carryover of less-polar substances could also be anticipated in 
crude preparations (18,19). In vivo assessment of crude medicinal plant extracts 
against M. tuberculosis is very difficult, and to establish the efficacy of these 
extracts, the animal model must closely resemble human infection. Gangadharan 
et al (46) have shown, at 4 weeks after infection, that the lungs of untreated 
infected mice exhibited histiocytic proliferation in the alveoli and alveolar septa, 
involving approximately 50% of the parenchymal area. Thus, the activities of 
medicinal plant extracts in these conditions might be different from those in an 
early infection. A chronic established infection, closer to the human infection, is 
more difficult to eradicate than an early acute infection. 
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We evaluated in this model of established infection of C57BL/6 mice with M. 
tuberculosis H37Rv strain the effects of crude medicinal plant extracts used by 
traditional doctors as a mixture of different plants or singly to treat tuberculosis. 
Traditional doctors combine known plants for treating tuberculosis because of 
their ability to act synergistically or because of treating different symptoms of 
the same disease. 
Our studies have revealed that none of the tested medicinal plant extracts 
showed any activity against M. tuberculosis. This might be because the extracts 
were not being absorbed in the gastric system of the mouse or not enough active 
material was distributed to the sites of infection since these materials are likely 
to be in very low concentrations in these complex mixtures. Metabolic activity of 
mice is different from that of human and this might have been another possible 
contributing factor in our study. Our experiments also show that some plant 
extracts are toxic at very high concentrations and they lead to death. However, in 
some cases death was due to an artefact by gavage. 
Testing medicinal plants for long-term treatment might show different results 
from our 2 weeks treatment model. It might also be important to start treatment 
immediately after infection to save time. Intravascular injection of mice with 
medicinal plants or giving test compounds in drinking water might also be 
important. Although the pathophysiology of tuberculosis in mice is different 
from that in humans, mice remain the best and most economical option for initial 
therapy evaluation (20). The discriminant power of this model is confirmed by 
the good activity of the positive control, INH-RIF combination, against 
established experimental infection. 
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CHAPTER4 
IMMUNOSTIMULATORY EFFECTS OF PLANT EXTRACTS ON CYTOKINE 
INDUCTION AND MICROSCOPIC ANALYSIS OF INFECTED ORGANS 
4.1 INTRODUCTION 
Among bacterial infections, mycobacterial diseases have the highest morbidity 
and mortality rates worldwide (21). This is primarily true for the causative 
agents of tuberculosis and leprosy, M. tuberculosis and M. leprae. Acquired 
cellular immunity to M. tuberculosis infection is characterized by the emergence 
of a population of protective CD4 T cells that secrete cytokines, resulting in local 
activation of macrophages and the recruitment of monocytes to initiate 
granuloma formation (22). The kinetics of this protective immunity, which leads 
to the control and containment of the infection, and the onset of bacterial 
clearance, is closely associated with the kinetics of emergence of CD4 T cells that 
secrete large amounts of the cytokine IFN-y. 
In vivo and in vitro infection with M. tuberculosis results in the secretion of 
numerous cytokines. Among the secreted cytokines TNF-a and IL-12 have 
powerful immunopotentiating effect. It also has the ability to initiate the 
development of Thl phenotype in naive T cells and the ability to potentiate IFN-
Y production in antigen-activated Thl cells. 
M. tuberculosis persists in macrophages within a granuloma in the organs of 
infected hosts. The granuloma consists of macrophages and giant cell, T cells and 
fibroblasts. In this chapter, the type and presence of granuloma in plant treated 
mice was determined and the cytokine induction by plant extract was 
determined. 
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4.2 MATERIALS AND ME1H0DS 
4.21 Bleeding of mice 
Mice were anesthetized with diethyl ether. The sternum of the mouse was lifted 
and a 1ml syringe fitted with a 27,5 gauge needle (Sterilin) inserted under the 
sternum into the heart. Blood from the heart was collected and the plunger 
withdrawn gently. The collected blood was transferred into an eppendorf tube 
(Sterilin) and centrifuged at 14 OOOrpm for 10 minutes. Serum was then collected 
into a new eppendorf tube and stored at -70°C until use. 
4.22 Cytokine measurements in serum 
Serum was thawed before detection of cytokines by sandwich ELISA method 
(Enzyme Linked Immunosorbent Assay). The concentration of the cytokines IL-
12 and IFN-y was measured. Nunc-Maxisorp 96 well microtiter plates were 
coated with 100µ1/well of the appropriate coating antibodies (biotin rat anti-
mouse IFN-y and IL-12p40), diluted in 'coating buffer' (0.1 %BSA/PBS/.02% 
sodium azide[Merck]) and incubated at 4°C overnight. Plates were washed three 
times with PBS and incubated with 150µ1 blocking buffer (4% BSA/PBS/0.04% 
sodium azide) for 2 hours at 37°C to block residual binding sites on the plastic. 
Plates were next washed four times with washing buffer (0.05% Tween20 
[Sigma]/PBS/0.01 % sodium azide) and incubated with 50µ1/well samples 
diluted 3-fold in dilution buffer and 50µ1/well appropriate cytokine standards 
included in 12 three-fold dilutions. This was then incubated overnight at 4oC. 
After incubation the plates were washed again and incubated with 50µ1/well of 
the capture antibody (see appendix) for 2 hours at 37°C. The plates were then 
washed and alkaline phosphatase labeled streptavidin (1/1000) added at 
50µ1/well and incubated for 1 hour at 37°C. The substrate P-Nitrophenol-
Phosphate (Boehringer Mannheim) was diluted in substrate buffer 50µ1 was 
added to each well. The plates were read at 405/ 492 nm in a microplate 
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spectrophotometer (Molecular Devices, Spectra MAXGemini). To stop the 
reaction 50µ1 lM sodium hydroxide was added. 
4.23 Organ preparation for histology 
Mice were sacrificed at week 2 and week 4 after infection. Lungs were 
aseptically removed from the week 2 mice. Lungs, liver and spleen were 
removed from the week 4 mice. Removed organ were weighed and a small 
portion of each tissue was placed in a solution of 10% formalin (4% 
formaldehyde in PBS pH 7.4). The organ sections were left in solution for 2 days 
to ensure killing of bacilli. Sections were then processed overnight and 
embedded in paraffin wax (Histosec Pastilles, Merck). Sections for Haematoxylin 
and eosin (H&E), as well as for Ziehl Neelsen (ZN) staining were cut to 4 µm 
thickness with a microtome (Leica, model RM-2125) and mounted on APES (3-
aminopropyltriethoxysilane, 99%) coated slides. 
4.24 Ziehl-Neelsen for Acid-fast Bacilli (AFB) 
Sections were dewaxed overnight by incubating in an oven at 56°C. Sections 
were placed on a staining rack and flooded with filtered Carbol Fuchsin, flamed 
until steaming and then left to cool for 5 minutes. The flaming-steaming process 
was repeated as before and followed by rinsing in water. Excess color was 
removed by rinsing with 1 % acid alcohol (1 % hydrochloric acid in 70% alcohol) 
for 30 seconds. The sections were washed in water before incubating in 25% 
H2S04 for 20 minutes at room temperature. Slides were washed in running water 
for 10 minutes to remove acid and counterstaining was done in Loefflers' 
methylene blue for 1 minute at room temperature. Sections were washed in 
water, dehydrated through alcohol (70%, 70%, 90%, 96% and absolute alcohol) 
into Xylol for a few seconds and mounted in Entellan mounting medium 
(Merck). 
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4.2.5 Haematoxylin and Eosin for morphology 
Sections were dewaxed overnight by incubating at 56°C in an oven. The next 
day, sections were rehydrated by immersing them once in xylol for 3 minutes 
and twice in the same solution for 1 minute each. Sections were then washed 
twice in absolute alcohol for 1 minute each, twice in 96% alcohol for 1 minute 
each and once in 70% alcohol for 1 minute. Alcohol from sections was washed in 
running water for 1 minute. The sections were placed in a haemotoxylin solution 
for 8 minutes and then washed in water for 1-2 minutes. Excess staining was 
removed by immersion in 1 % acid alcohol for 10 seconds, and the blue color 
retrieved by leaving sections in water for 30 minutes. Sections were 
counterstained in 1 % eosin for 2 minutes and then washed in water. Sections 
were then dehydrated by passing them through 70%, 96% alcohol and finally 
through xylol. The sections were mounted with entellan and coverslipped. 
1.26 Microscopic analysis of sections 
The microscopic sections were investigated with light microscope and 
photographs were taken. Quantitative analysis of sections was done to 
determine tissue alterations. 
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4.3 RESULTS 
ACID FAST BACILLI (AFB) 
Treated and untreated mice were examined for the presence of AFB in the lung, 
liver and spleen. Since plant extract A treated mice showed increased bacterial 
counts in the lungs, this increased growth of mycobacterium was visualized by 
the Ziehl-Neelsen staining. The lung sections of plant extract A treated mice at 
different doses contained abundant mycobacteria as compared to the untreated 
mice at week 4 (Fig 4.1). Untreated mice had few mycobacteria at 2 weeks as 
compared to 4 weeks. Increased mycobacterial growth of plant extract A treated 
mice was not dose dependant. INH-RIF treated mice did not show any 
mycobacteria in the lung, liver and spleen tissue sections. 
GRANULOMA FORMATION 
Treated and untreated organs of M. tuberculosis infected mice were examined for 
granuloma formations with Haematoxylin and Eosin staining. Due to the 
inability of the plant extract to clear the bacilli, we investigated whether proper 
granulomas were formed; especially in plant extract A treated mice. This was 
done to determine the control of infection by plant extract A treated mice. Mice 
treated with plant extract A at different doses showed the presence of increased 
granulomas in the lungs. Lung tissues in treated group were compact and 
consisted of little air spaces. Mice treated with INH-RIF for 2 weeks showed 
infiltration with lymphocytes and macrophages in the lungs, but there was no 
granuloma formation. At 2 weeks after infection, the lungs of untreated mice 
showed no granuloma formation. Lung tissue was infiltrated with recruited 
macrophages and lymphocytes. Typical granulomas were found at 4 weeks post-
infection in the lung of untreated mice. 
CYTOKINE LEVEL IN SERUM 
We examined the expression of IL-12 in serum from treated and untreated mice 
infected with M. tuberculosis, because of its role in activating immune response 
and in engendering protective immunity by promoting the development of a Thl 
T-cells. IL-12 is essential in control of M. tuberculosis infection. IL-12 levels were 
measured at 4 weeks postinfection by sandwich ELISA. This was done to 
determine if plant extracts had immunostimulatory effects on infected mice. 
There was no significant difference between positive (INH-RIF) and negative 
(untreated) control mice (p< 0.005) in the production of IL-12p40. IL-12p40 
production was virtually suppressed in plant extract A treated mice, both at 100 
and 500mg/kg. 
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Figure 4.1. Histopathological studies (Ziehl-Neelsen stain) of lung tissues from treated and 
untreated C57BL/6 mice infected with M. tuberculosis (n = 5). Mice infected with 1 X 107 CFU of 
H37Rv organisms. Infected mice were sacrificed, lungs asceptically removed and prepared for 
histological analysis. (A) INH-RIF treated mice - week 4. (B) Untreated mice - week 2. (C) 
Untreated mice - week 4. (D, E, F) Mice treated with different doses (10, 100, 500 mg/kg) of 
plant extract A, respectively - week 4. Original magnification XlOO. 
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Fig 4.2. Histopathological studies (Haematoxylin and Eosin stain) of lung tissues from treated 
and untreated C57BL/ 6 mice infected with M. tuberculosis. Mice infected with 1 X 107 CFU of 
H37Rv organisms (n = 5). Mice were sacrificed, lungs aseptically removed and prepared for 
histological analysis. (A) INH-RIF treated mice. (B) Untreated mice - week 2. (C) Untreated mice 
- week 4. (D, E, F) Mice treated with different doses (10, 100, 500 mg/kg) of plant extract A, 
respectively - week 4. Original magnification X4. 
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Fig 4.3. Effect of plant extract A on the production oflL-12p40 from serum of M tuberculosis infected mice (n = 
5). Infected mice were treated for 2 weeks with different doses of plant extract A. Serum samples were assayed by 
sandwich ELISA. Negative control (NC) - untreated mice. Positive control (PC) - INH-RIF treated mice. The data 
represents the means (solid bars) and± standard deviations (error bars). 
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4.4 DISCUSSION 
The immune response to all pathogens is at least in part dependent on cytokines, 
which regulate all cells of the immune system. M. tuberculosis is no exception and 
in fact strongly induces cytokines during infection. IL-12, which is induced 
during mycobacterial infection, is crucial in controlling M. tuberculosis infection 
(23). In our studies, we further evaluated the immunostimulatory effects of 
medicinal plant extracts on cytokine induction and the histology of infected 
organ. 
Our mouse model of mycobacterial aerosol infection demonstrates that in the 
presence of IL-12, cells that are necessary for granuloma formation were 
recruited leading to a successful granuloma formation. INH-RIF treatment did 
not interfere with the production of IL-12 and the lung tissue was cleared of the 
bacteria indicating the healing activity of IHN-RIF combination. 
IL-12 is one of the principal cytokines that drive the immune system to a Th-1 
response, critical in the control of M. tuberculosis infection. Flynn et al (22) have 
shown that in the absence of IL-12, mice infected with M. tuberculosis were 
susceptible to infection and had a greatly increased bacterial burden. In another 
study, Cooper et al (23) have also shown that the absence of the bioactive IL-12 
molecule results in unrestrained growth of M. tuberculosis bacteria in all target 
organs after infection. The absence of IL-12, also leads to the reduction in the 
level of IFN-y and the expression of TNF-a is delayed. The delay of IFN-y 
expression results in the delay of the induction of macrophage activation, which 
is mirrored by the lower number of lymphocytes in the lung granuloma. This 
leads to a formation of a defective granuloma. Therefore, the suppression of IL-
12p40 production in M. tuberculosis infection after treatment with plant extract A 
was puzzling. The suppression of IL-12p40 in plant extract A treated mice did 
not demonstrate residual resistance to M.tuberculosis which is dependant on the 
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presence of endogenous IL-12p40. Thus rather than curtailing the infection, 
treatment with plant extract A may favor the survival and multiplication of M. 
tuberculosis in the host. This suppression might have been caused by production 
of other cytokines such as IL-4, IL-10 or TGFB. This reasoning would not 
contradict the increased bacterial burden observed in mice treated with plant 
extract A. 
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CHAPTERS 
OVERALL CONCLUSION 
Tuberculosis is acquiring increasing importance throughout the world especially 
with the advent of Human Immunodeficiency Virus (HIV) infections. Together 
with HIV, it is the worst infectious disease facing the world. In South Africa, we 
are burdened by one of the worst tuberculosis epidemics ever recorded. The 
highest rates are recorded from the Western, Eastern and Northern Cape, where 
incidence figures (Chapter 1) are more than double those reported from the other 
provinces. 
A once-off contact with traditional doctors when collecting information about the 
use of medicinal plants creates the impression that scientists exploit their 
knowledge and when activity is found they are not acknowledged for their 
contribution. This leads to a situation where traditional doctors end-up not 
trusting scientists and refusing to share information on the use of medicinal 
plants. Regular contacts should be maintained so that traditional doctors get 
feedback of the laboratory experiments done on medicinal plants and what they 
mean. Although the perception of tuberculosis between "Western" medicine and 
traditional medicine (Chapter 2) is different, traditional doctors should also be 
taught what western doctors know about tuberculosis (e.g. symptoms and cause) 
A colleague, Eliya Madikane, also tested the plant extracts used in this study in 
vitro by the Luciferase Reporter Mycobacteriophage assay (LRP). He tested 
organic extracts of the same plants against Mycobacterium aurum. His results 
show activity by plant extract I. His preliminary results of fractions from this 
extract tested against H37Rv also show some activity. In our study, water was 
used, as the solvent for extraction, there is the possibility that the active 
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used, as the solvent for extraction, there is the possibility that the active 
ingredients could have been insoluble in water and as such not extracted in 
sufficient amounts. 
We could not identify any activity in the in vivo aerosol H37Rv infection studies 
(Chapter 3). This does not mean that these medicinal plants are not effective at all 
against other chest diseases. Although these plants are reported as being used to 
treat tuberculosis or symptoms similar to that caused by it, it is possible that 
these plants are effective against colds, coughs or chest pains caused by diseases 
other than tuberculosis. Laboratory tests to confirm tuberculosis in patients 
treated by traditional doctors should be done before and after treatment with 
medicinal plants so that efficacy of treatment can be identified. It is well 
established that most drugs have adverse effects. However, in contrast to herbal 
products, conventional drugs undergo trials prior to registration by the 
Medicines Control Council (MCC), followed by post-marketing surveillance that 
documents adverse effects. We found that plant extract B was toxic at high 
concentrations (1000mg/kg) and traditional doctors must be informed to avoid 
complications associated with the prescription of that plant. This should be seen 
as our moral obligation to protect the health and safety of our people with 
respect to use of herbal medicines. 
Plant extract A suppressed the immune production of IL-12 (Chapter 4) in 
infected mice. This extract might be useful in treating Thl mediated autoimmune 
pathologies caused by the overproduction of IL-12 (e.g. systemic sclerosis). 
Ethanol has been shown to up-regulate IL-12 production in human monocytes 
and indeed, increased serum IL-12 levels have been associated with chronic 
alcoholism (73). It is therefore possible that the effect of ethanol on IL-12 can be 
counteracted by the use of plant extract A, but as to whether plant extract A also 
suppresses IL-12 production in humans remains to be established. 
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The mouse model has been used to test the antituberculous activity of several 
drugs because it is highly reproducible and inexpensive. The course of the 
disease that follows experimental infection with Mycobaderium tuberculosis is 
different from that of the disease in humans. However, the mouse model is able 
to reproduce bacillary populations of comparable size to those observed in the 
lung cavity of human tuberculosis (38). Therefore the mouse tuberculosis model 
can be safely used for discovering prototypes of new compounds with new 
activities against Mycobaderium tuberculosis. 
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APPENDIX A 
SOXHLET APPARATUS FOR PLANT EXTRACTION 
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Appe11dix A 
C 
Principle of the Soxhlet Extraction: The plant material is placed in A, the 
Soxhlet apparatus. The apparatus is then fitted onto flask C, which contains the 
solvent. The solvent is boiled gently. Vapour passes up through the tube E 
which is condensed by the condenser D. The condensed solvent falls into A and 
slowly fills the body of the Soxhlet. When the solvent reaches the top of tube F, 
it siphons over into flask C and thus removes that portion of the substance 
which it has extracted in A. This process is repeated automatically until the 
extraction is complete, usually over several hours. The extracted compound is 
then isolated from C by evaporating the solvent (84). 
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APPENDIXB 
EXPERIMENTAL REAGENTS 
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APPENDIX B 
A. BACTERIOLOGICAL REAGENTS 
A.1. Difeo Middlebrook 7H10 Agar (M7H10) 
19g M7H10 agar and 
5ml glycerol were made up to 900ml with 
distilled water (H20) and autoclaved at 121 oC for 10 minutes. 
The solution was allowed to cool to 550c and 100ml of oleic acid albumin 
catalase (OADC) or albumin dextrose catalase (ADC) added. Seven millilitres 
of the agar solution was poured per side in sterile duplicate petridishes 
(Sterilin). When set, the plates were stored inverted at 4°C. the agar was 
brought to room temperature 1 or 2 hours before use. 
A.2. Albumin Dextrose Catalase (ADC) 
25g Bovine Serum Albumin (BSA) 
10g Glucose D, and 
4.25g Sodium Chloride (NaCl) were dissolved in 
500ml distilled H20 
the solution was then filtered first through a 0.45µm millipore filter. Hundred 
millilitre aliquots were made and stored at 40c. 
A.3. 0.9% Saline solution 
9g of NaCl was dissolved in 
100ml of distilled H20 and then autoclaved at 121 oc for 30 minutes. The 
solution was stored at room temperature. 
A.4. Homogenizing Buff er 
0.9% NaCl 
0.04 % Tween 80 
dissolved in distilled H20. 
Autoclaved for 30 minutes at 1210c and stored at room temperature. 
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B. GENERAL REAGENTS 
B.1. 10 X Phosphate Buffered Saline (PBS) 
80g NaCl (1.37M) 
2.4g KH2P04 
2g KCl (0.03M) and 
14.4g Na2HP04.2H20 were dissolved in 
900ml distilled H20 
The pH was adjusted to 7.4 and made up to 1000ml with distilled H20. The 
solution was sterilized through a 0.45µm millipore filter and stored at room 
temperature. The buffer was diluted 1/10 as a working solution. 
C. ELISA REAGENTS 
Bovine serum albumin (BSA) Fraction V Cat # 735 086 Boehringer Mannheim 
4-Nitrophenylphosphat (PNPP) Cat# 738 352 Boehringer Mannheim 
Diethanolamine Cat# Art 803116 Merck 
Instant milk powder (Spar Supermarket) 
Streptavidin-Alkaline phosphatase Cat # 13043E Pharmingen 
C.1. Coating Buffer 
(0.02%) 0.2g NaN3 was dissolved in 
1000ml of 1 X PBS (pH 7.4) 
The solution was sterilized through a 0.45µm millipore filter and stored at 
40c. 
C.2. Dilutin Buff er 
10g (1 % ) BSA and 
0.2g (0.02%) NaN3 were dissolved in 
1 X PBS (pH 7.4) and made up to 1 litre, sterile filtered through a 0.45µm 
millipore filter and stored at 40c. 
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C.3. Blocking Buff er 
20g (2%) Milk powder (Instant milk powder from Spar) or 40g (4 % ) BSA and 
0.2g NaN3 (0.02%) was added to 
100ml 10 X PBS and made up to lL with distilled H20. 
The solution was stirred until properly dissolved, filterd through Whatmann 
filter paper no 1 and sored at 40c. For BSA, the solution was filtered through a 
0.45µm millipore filter. 
C.4. 20 X Washing Buffer 
20g KCl, 
20g KH2P04, 
144g Na2HP04.2H20, 
800g NaCl, 
SOML NaCl, 
SOML Tween 20, and 
100ml 10% NaN3 were dissolved in 
SL of distilled H20. 
The solution was filter sterilized through a 0.45µm millipore filter and stored 
at 40c. The buffer was diluted 1/20 as a working solution. 
C.5. Substrate Buff er 
0.3g NaN3, 
97ml Di-ethanolamine (liquefy in 37°C waterbath), and 
0.8 MgCh.6H20 were dissolved in 
700ml distilled H20. 
The pH was adjusted to pH 9.8 with 
10M HCl and then made up to lL. Filter sterilized through a 0.45µm millipore 
filter and stored at 40c. 
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D. HISTOLOGY REAGENTS 
D.1. Coating slides with APES (3-aminopropyltriethoxysilane, 99%) 
Slides were washed in 1 % Teepol diluted in distilled H20 for 10 minutes at 
room temperature shaking. Slides were then washed in running tap H20 for 1 
hour and dried at 6QOC for 4 hours or overnight at 37°C. Dried slides were 
then immersed 10 X in 3.3% APES in distilled H20. Slides were then dried 
overnight at 370c, packed in boxes and stored at room temperature for later 
use. 
D.2. Mayers Haematoxylin 
Dissolve each of the following compounds in order ensuring that each one 
has dissolved properly before adding next one. 
lg Haematoxylin 
50g Ammonium alum (Aluminium ammonium sulphate) or Potassium alum 
(Aluminium potassium sulphate) 
0.2g Sodium iodate 
lg Citric acid 
50g Chloral hydrate 
Filter through Whatmann paper no 1 and store in dark place at room 
temperature. 
D.3. Eosin 
150ml 1 % Eosin in distilled H20 (2parts) 
75ml 1 % Phloxine in distilled H20 (lpart) 
225ml distilled H20 
One drop formalin or thymol was added to the 1 % eosin for preservation. 
Filter through Whatmann filter paper no 1 and store at room temperature. 
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D.4. Carbol Fuchsin 
Stock: 6% Basic Fuchsin in absolute alcohol 
Staining solution : 10ml stock 
90ml 5% carbolic acid (phenol) in distilled H20. 
Filter the solution through Whatmann filter paper no 1 and store the solution 
at room temperature. 
D.S. Buffered Formalin (fixative for tissues) 
10ml formaldehyde (40% w /v formaldehyde solution) 
900ml PBS (pH 7.4) 
store at room temperature in a dark bottle. 
D.6. Loeffers' Methylene Blue 
Stock: 0.8% Methylene blue in absolute alcohol 
Staining solution: 30ml stock 
99ml distilled H20 
1ml 1% KOH 
Filter the solution through Whatmann filter paper no 1 and store at room 
temperature. 
D.7. Schiffs (PAS) Reagent 
Dissolve lg Basic Fuchsin in 200ml boiling distilled H20 in stopped lL flask. 
Shake for 5 minutes. 
Cool to S0°C, filter , add20ml lN HCI to filtrate. 
Store 18-24 hours in dark. 
Add 2g activated charcoal - shake 1 minute. 
Filter - store at 0-40C in dark. 
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